MarketWatch

Drug that reduces iron levels in affected brain regions has a possible disease-modifying effect in people with multiple system atrophy

The MarketWatch News Department was not involved in the creation of this content. HONOLULU, Oct. 5, 2025 /PRNewswire/ -- An orally administered drug to redistribute excess iron and lower cellular ...
PharmiWeb

Lundbeck advances Parkinson’s research with new Phase 1b data at AD/PD™ 2026

Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at the 2026 AD/PD™ Conference·     Data evaluated safety, tolerability, ...
PMLive

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...
Seeking Alpha

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...
Nasdaq

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Lundbeck Advances Parkinson's Research With New Phase 1B Data At AD/PDTM 2026

Lundbeck Advances Parkinson's Research With New Phase 1B Data At AD/PDTM 2026. Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented ...